BioSpace News Archive

Policy

ClearMind Biomedical Clears FIM Clinical Trial for Least Invasive ICH Treatment to Date

ClearMind Biomedical’s novel neurosurgical endoscope, the Axonpen System, has completed its First in Man clinical trial in Taiwan with outstanding results.

July 6, 2022
·
3 min read
Inactivation of Suv39h1 Enhances Anti-Tumor Immune Response by Increasing T Cell Activity and Decreasing T Cell Exhaustion During Anti-PD-1 Treatment

Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced a publication in Nature Communications demonstrating that the histone lysine methyltransferase enzyme Suv39h1 plays not only a key role in T cell persistence, but also in T cell activation and exhaustion.

July 6, 2022
·
4 min read
C4X Discovery Receives Sanofi Milestone Payment

C4X Discovery Holdings plc, a pioneering Drug Discovery company, announces that it has received a milestone payment of €3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021.

July 6, 2022
·
2 min read
Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Five Presentations Will Highlight Findings from the XIPERE ® Pivotal Phase 3 Program.

July 6, 2022
·
7 min read
Business

Nevro to Report Second Quarter 2022 Financial Results

Company to Host Conference Call on Wednesday, August 3, 2022 at 1:30 pm PT / 4:30 pm ET.

July 6, 2022
·
2 min read
Genetown

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2022

AVROBIO, Inc. announced that the company has granted an aggregate of 37,500 restricted stock units to three new employees as inducement awards under the company’s 2019 Inducement Plan.

July 6, 2022
·
5 min read
Biotech Beach

BioTools Innovator Announces Top 14 Life Sciences Companies Selected for 2022 Cohort

BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced that 14 companies have been selected to participate in its annual program.

July 6, 2022
·
5 min read
Drug Development

Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder

Clairvoyant Therapeutics, a Canadian biotech company, is pleased to announce it has initiated the first of 15 planned sites for CLARITY, the company’s Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder (AUD) (formerly called alcoholism).

July 6, 2022
·
2 min read
Genetown

Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M

Pressure BioSciences, Inc. today announced the Company’s participation in the July 6th Emerging Growth Investor Conference.

July 6, 2022
·
6 min read
Business

Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board

Smart Immune SAS announced today that Dr. Marcel van den Brink has been appointed Chairman of its Scientific Advisory Board.

July 6, 2022
·
2 min read